Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on November 3, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Teva announced financial results for the quarter ended September 30, 2026.
Teva Pharmaceutical Industries Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Teva announced financial results for the quarter ended September 30, 2026
- Full results, including operating performance and outlook, are contained in Exhibit 99.1‑
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $4.395B, down 2% YoY as U.S. generic revenue fell 39%, primarily from lenalidomide competition
- Innovative brands generated approximately $1.1B, up 33% locally, supporting higher 2026 outlooks for AUSTEDO, AJOVY and UZEDY
- Gross margin expanded to 55.5% from 51.4%; non-GAAP operating margin reached 31.7% from 28.9%
- GAAP EPS fell to $0.20, while non-GAAP EPS rose 10% to $0.86; legal settlements and impairments pressured reported earnings
- WELTRUZA approval and BXCL-501 acquisition strengthen neuroscience growth, with UZEDY and WELTRUZA peak sales potential of $1.5B-$2.0B
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teva Pharmaceutical Industries Ltd 8-K filings
Get the next TEVA 8-K as it lands
Follow TEVA for push alerts, or ask the research agent what this filing means.